The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes

被引：0
|
作者：
Nauck, M. A. [1 ]
Petrie, J. R. [2 ]
Sesti, G. [3 ]
Mannucci, E. [4 ]
Courreges, J-P [5 ]
Atkin, S. [6 ]
Duering, M. [7 ]
Jensen, C. B. [7 ]
Heller, S. [8 ]
机构：
[1] Ctr Diabet, Bad Lauterberg Im Harz, Germany
[2] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland
[3] Magna Graecia Univ Catanzaro, Catanzaro, Italy
[4] Careggi Teaching Hosp, Florence, Italy
[5] Gen Hosp, Narbonne, France
[6] Hull York Med Sch, Kingston Upon Hull, N Humberside, England
[7] Novo Nordisk, Soborg, Denmark
[8] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England
来源：
DIABETOLOGIA | 2012年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [21] A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes
    Webb, Neil
    Orme, Michelle
    Witkowski, Michal
    Nakanishi, Rie
    Langer, Jakob
    DIABETES THERAPY, 2018, 9 (03) : 973 - 986
  • [22] Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin
    Jose Gorgojo-Martinez, Juan
    Malkin, Samuel J. P.
    Martin, Virginia
    Hallen, Nino
    Hunt, Barnaby
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (02) : 193 - 203
  • [23] Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes
    Kapitza, C.
    Heise, T.
    Birman, P.
    Jallet, K.
    Ramis, J.
    Balena, R.
    DIABETIC MEDICINE, 2009, 26 (11) : 1156 - 1164
  • [24] A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes
    Neil Webb
    Michelle Orme
    Michal Witkowski
    Rie Nakanishi
    Jakob Langer
    Diabetes Therapy, 2018, 9 : 973 - 986
  • [25] Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
    Raffaella Gentilella
    Irene Romera
    Claudia Nicolay
    Raffaella Buzzetti
    Luis Alberto Vázquez
    Giorgio Sesti
    Diabetes Therapy, 2019, 10 : 1113 - 1125
  • [26] Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
    Gentilella, Raffaella
    Romera, Irene
    Nicolay, Claudia
    Buzzetti, Raffaella
    Alberto Vazquez, Luis
    Sesti, Giorgio
    DIABETES THERAPY, 2019, 10 (03) : 1113 - 1125
  • [27] The effect of LY2189265 (GLP-1 analogue) once weekly on HbA1c and beta cell function in uncontrolled type 2 diabetes mellitus: the EGO study analysis
    Umpierrez, G.
    Blevins, T.
    Rosenstock, J.
    Cheng, C.
    Bastyr, E.
    Anderson, J.
    DIABETOLOGIA, 2009, 52 : S59 - S59
  • [28] Bydureon, the once weekly GLP-1 agonist reported to be less effective in reducing Hba1c and weight compared with Liraglutide
    Idris, Iskandar
    DIABETES OBESITY & METABOLISM, 2011, 13 (11): : 1060 - 1060
  • [29] Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting
    Chioma Uzoigwe
    Yuanjie Liang
    Sarah Whitmire
    Yurek Paprocki
    Diabetes Therapy, 2021, 12 : 1475 - 1489
  • [30] Liraglutide, a human GLP-1 analogue, maintains greater reductions in HbA1c, FPG and weight than glimepiride over 2 years in patients with type 2 diabetes: LEAD-3 extension study
    Garber, A. J.
    Henry, R.
    Ratner, R.
    Hale, P.
    Chang, C. T.
    Bode, B.
    DIABETOLOGIA, 2009, 52 : S287 - S288
12345